KSC · 004310.KS
Hyundai Pharmaceutical Co., Ltd.
₩6,570-₩110 (-1.65%)
Hyundai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.83% below the high.
Loading market information…
KOE · 048530.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
iNtRON Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
iNtRON Biotechnology, Inc.’s forward annual dividend is ₩100 per share, paid annual. The forward yield is 3.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
iNtRON Biotechnology, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of ₩17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow iNtRON Biotechnology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iNtRON Biotechnology, Inc. is a global developer of biopharmaceutical solutions focused on averting and remedying human ailments. Its development efforts encompass a range of bacteriophage and endoricin-based therapeutics. This company, which has its primary operations in Seongnam-si, South Korea, was established in 1999.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | Mar 11, 2025 | -₩45 | ₩1.52B |
|---|
| Q3 2024 | Nov 19, 2024 | -₩40 | ₩1.21B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩6,570-₩110 (-1.65%)
Hyundai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.83% below the high.
₩12,330-₩20 (-0.16%)
CKD Bio Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.48% below the high.
₩5,660-₩70 (-1.22%)
Ildong Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 67.04% below the high.
₩841-₩36 (-4.1%)
CG Invites Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
₩4,060-₩25 (-0.61%)
Sugentech Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.79% below the high.
₩1,882+₩21 (+1.13%)
Cellid, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 60.46% below the high.
₩4,675-₩185 (-3.81%)
Encell Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
₩2,875-₩155 (-5.12%)
Oncocross Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 80.16% below the high.
